First, the authors tested the expression levels of EZH2 and the proliferation marker Ki67 in 30 cases of less aggressive BCC histologic subtypes and 30 cases of more aggressive histologic subtypes (morpheaform, infiltrative, and micronodular). Here, EZH2 is linked to skin basal cell carcinoma.